Purinergic Signaling and the Postmenopausal Heart

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT06015776
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 88 Years
Healthy Volunteers
Not accepted

Interventions

  • Gender — OTHER
    Differences between men and women will be observed

Study Details

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Key Dates

Start date
Jul 1, 2019
Status verified
Jan 2026
Primary completion
Jun 30, 2030
Completion
Jun 30, 2030

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Men
    Men who are undergoing cardiac surgery
  • Arm: Women
    Women who are undergoing cardiac surgery

Primary Outcome Measure

Comparative quantification of expression of CD39 and adenosinergic receptors [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215
Robina Matyal, MD
[email protected]
6176401208

Find similar trials in Boston, MA

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Beth Israel Deaconess Medical Center· Boston, MA

Related Studies